GSK has agreed to acquire Canada’s Bellus Health for around $2 billion, bolting on a late-stage drug candidate for chronic refractory cough. The $14.75-per-share deal will add P2X3 antagonist ...

Pharmacists are seeking clarification from the DCGI regarding the handling of recently banned cough syrups for children under ...

Anyone in the U.S. who bought any flavor Robitussin product containing dextromethorphan (or DXM) and labeled as “non-drowsy” between Feb. 16, 2016, and Jan. 21 are eligible to file a claim, according ...